{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/clinical-trial-safety-reporting-and-pharmacovigilance”
},
“@id”: “https://www.clinicalstudies.in/clinical-trial-safety-reporting-and-pharmacovigilance”,
“headline”: “SOP for Clinical Trial Safety Reporting and Pharmacovigilance”,
“name”: “SOP for Clinical Trial Safety Reporting and Pharmacovigilance”,
“description”: “Comprehensive SOP describing sponsor, investigator, and CRO responsibilities for clinical trial safety reporting and pharmacovigilance in New Zealand, ensuring compliance with Medsafe, HDEC, and ICH GCP requirements.”,
“keywords”: “Clinical trial safety reporting NZ, SOP for safety management NZ, SOP for SAE reporting NZ, SOP for SUSAR reporting NZ, SOP for expedited safety submissions NZ, SOP for Medsafe safety compliance, SOP for HDEC safety notifications, SOP for PV responsibilities NZ, SOP for sponsor safety reporting NZ, SOP for investigator safety obligations NZ, SOP for CRO safety support NZ, SOP for ICSR submissions NZ, SOP for DSUR submissions NZ, SOP for trial subject safety NZ, SOP for safety database NZ, SOP for adverse event documentation NZ, SOP for inspection readiness safety NZ, SOP for safety data archiving NZ, SOP for safety governance NZ, SOP for privacy compliance safety NZ, SOP for CAPA safety findings NZ, SOP for ethics safety compliance NZ, SOP for trial oversight safety reporting NZ, SOP for GCP safety compliance NZ, SOP for pharmacovigilance audits NZ”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Clinical Trial Safety Reporting and Pharmacovigilance SOP

Purpose

The purpose of this SOP is to establish processes for safety reporting and pharmacovigilance in clinical trials conducted in New Zealand. It ensures compliance with Medsafe, HDEC, and ICH GCP requirements to protect participant safety and ensure regulatory reporting obligations are met.

Scope

This SOP applies to all sponsor-led and investigator-initiated clinical trials in New Zealand. It covers SAE/SUSAR reporting, ICSR submissions, DSUR reporting, expedited safety notifications, safety database management, and PV audits. It applies to sponsors, investigators, CROs, PV officers, and QA teams.

Responsibilities

• Sponsor: Oversees pharmacovigilance systems, ensures timely safety reporting, and submits DSURs to Medsafe/HDEC.
• Principal Investigator (PI): Identifies, documents, and reports SAEs within 24 hours, and ensures site-level reporting compliance.
• Clinical Research Coordinator (CRC): Supports PI in safety reporting, documentation, and follow-up.
• Regulatory Affairs (RA): Manages submissions to Medsafe/HDEC, ensures acknowledgment of SUSAR/SAE reports.
• PV Officer: Maintains safety database and prepares ICSRs/DSURs.
• Quality Assurance (QA): Conducts pharmacovigilance audits and ensures corrective actions are implemented.
• CRO: Provides pharmacovigilance support when delegated by sponsor.

Accountability

The sponsor’s Qualified Person for Pharmacovigilance (QPPV) is accountable for ensuring compliance with PV requirements. The PI is accountable for site-level safety reporting accuracy and timeliness.

Procedure

1. SAE Reporting

1. Document all SAEs in SAE Form (Annexure-1) within 24 hours of awareness.
2. Notify sponsor PV team immediately for evaluation.
3. Retain records in ISF and TMF.

2. SUSAR Reporting

1. Fatal or life-threatening SUSARs: report to Medsafe/HDEC within 7 calendar days; provide follow-up within 8 days.
2. Other SUSARs: submit within 15 calendar days.
3. Record all SUSARs in SUSAR Log (Annexure-2).

3. ICSR Submissions

1. Prepare ICSRs in compliance with Medsafe requirements.
2. Submit electronically via approved PV system.

4. DSUR Submissions

1. Prepare DSUR annually, summarizing safety data across all regions.
2. Submit to Medsafe within 60 days of data lock point.

5. Privacy and Confidentiality

1. De-identify participant data before submissions.
2. Ensure compliance with Privacy Act 2020.

6. Pharmacovigilance Audits

1. QA team conducts annual PV audits.
2. Maintain CAPA for identified findings in PV Audit Log (Annexure-3).

7. Archiving

1. Archive SAE, SUSAR, ICSR, and DSUR records in TMF and ISF.
2. Maintain records for at least 10 years post-trial.

Abbreviations

• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• ICSR: Individual Case Safety Report
• DSUR: Development Safety Update Report
• PI: Principal Investigator
• CRC: Clinical Research Coordinator
• PV: Pharmacovigilance
• QPPV: Qualified Person for Pharmacovigilance
• RA: Regulatory Affairs
• QA: Quality Assurance
• ISF: Investigator Site File
• TMF: Trial Master File
• HDEC: Health and Disability Ethics Committees
• Medsafe: Medicines and Medical Devices Safety Authority

Documents

1. SAE Form (Annexure-1)
2. SUSAR Log (Annexure-2)
3. PV Audit Log (Annexure-3)

References

• Medsafe — Medicines and Medical Devices Safety Authority
• HDEC — Health and Disability Ethics Committees
• New Zealand Privacy Act 2020
• ICH E6(R2) Good Clinical Practice
• ICH E2F — DSUR Guidelines

Version: 1.0

Approval

Annexures

Annexure-1: SAE Form

Annexure-2: SUSAR Log

Annexure-3: PV Audit Log

Revision History

For more SOPs visit: Pharma SOP.